Networks of Innovation
Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895–1995

How private organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market antitoxins and vaccines.

Louis Galambos (Author), Jane Eliot Sewell (With)

9780521626200, Cambridge University Press

Paperback / softback, published 13 August 1997

288 pages, 4 colour illus.
22.7 x 15.3 x 2 cm, 0.44 kg

'The work is admirably referenced and will be of value to all who take an interest in the field of biologicals. It will repay careful reading by those involved in the management of innovation in the pharmaceutical industry.' John Hunt, The Pharmaceutical Journal

Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.

Preface
1. 1894: 'The foremost medical question of the day'
2. The Mulford story
3. A Sharp & Dohme interlude
4. The virology network and a new programme at Merck, Sharp & Dohme
5. Hilleman's innovations: first phase, measles-mumps-rubella
6. Dangerous interlude, Marek's Disease adjuvant 65, the Swine Flu drama
7. Transforming bacteriology: a second phase, meningitis, pneumonia, haemophilus, influenzae
8. New networks, new leadership: the Hepatitis B vaccines
9. Vaccine innovation in the nineties: new strategies, new structures, and public confrontations
A word about sources.

Subject Areas: History of medicine [MBX], Pharmaceutical industries [KNDP]